Clinical Trial Update: A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating 18F-AlF-NOTA-octreotide as a PET/CT imaging tracer for neuroendocrine neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasms

Drugs mentioned

• [18F]AlF-NOTA-octreotide (18F-AlF-NOTA-octreotide)

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Neuroendocrine Neoplasm | Phase 1, Phase 2 | Status: UNKNOWN